On January 5, 2026, Catherine A. Sohn, a member of Altimmune’s board, acquired an additional 500 shares of the company’s common stock, raising her total ownership to 1,500 shares. This purchase underscores insider confidence in Altimmune’s pipeline and governance. Sohn’s increased stake follows a period of positive clinical and regulatory milestones for the company’s lead asset, pemvidutide, and positions her among the more significant individual shareholders, aligning her interests closely with those of institutional investors.

The U.S. Food and Drug Administration has awarded Breakthrough Therapy Designation to Altimmune’s investigational drug pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This designation is reserved for therapies that demonstrate substantial improvement over existing treatments on clinically significant endpoints. The decision accelerates the review pathway for pemvidutide and reflects the FDA’s recognition of its potential to address an area of high unmet medical need, potentially shortening the time to market and enhancing the value of Altimmune’s late-stage development program.

Altimmune’s 48-week Phase IIb trial of pemvidutide in MASH patients produced durable, dose-dependent improvements in non-invasive fibrosis markers and liver inflammation. Patients receiving the 1.8 mg dose achieved mean weight loss of 7.5%, while safety and tolerability remained consistent with earlier data, featuring a lower discontinuation rate versus placebo. Following a productive end-of-Phase II meeting with the FDA, the company has reached agreement on registrational Phase III trial parameters, including biopsy-based endpoints and a 52-week treatment duration. Plans call for testing a higher 2.4 mg dose and leveraging the FDA-qualified AIM-MASH AI pathology tool to support a potential accelerated approval pathway.